Amgen Inc. (Nasdaq:AmgnHe is one of Most of the S&P 500 shares denied their value now to buy now. On September 3, William Blair’s analyst Vipps Repeat a purchase rating on AMGEN Inc. (NASDAQ: AMGN) without revealing any price. The analyst admitted that the recent results of the Fortitude-101 showed a lower benefit than survival for Bemarituzumab in stomach cancer. However, he is still optimistic about the next stability 102.
Phips highlighted that despite the initial setback, the administration focused on the upcoming Fortede-102, which combines Bemarituzumab with chemotherapy and OPDIVO. The results of this experience are expected to be very important for organizational approval and market capabilities.
In addition, the AMGEN Inc. Portfolio remains (NASDAQ: AMGN), PHPPS expects the company’s strategy to adapt time tables and plans based on experimental results. He sees this flexibility as a positive indicator of long -term growth.
Amgen Inc. (NASDAQ: AMGN) is a biotechnology company that detects and develops drugs for serious diseases. It focuses on creating treatments for conditions with unparalleled medical needs.
Although we acknowledge the possibility of AMGN as an investment, we believe that some of the artificial intelligence shares provide greater potential in the upward direction and carry less risks on the negative side. If you are looking for a stock of artificial intelligence with less than very apprecia The best inventory of artificial intelligence in the short term.
Read the following: 30 stocks must double in 3 years and 11 stocks of hidden artificial intelligence for purchase now.
Detection: Nothing. This article was originally published in A monkey from the inside.
https://s.yimg.com/ny/api/res/1.2/Umivb7Omy8VqKH22zTmY9Q–/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/51e557354b24b248245adac46ac0da45
Source link